<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1733</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Включение тиазидного диуретика в комбинированную антигипертензивную терапию целесообразно</article-title><trans-title-group xml:lang="en"><trans-title>Adding а thiazide diuretic to combined antihypertensive therapy is clinically reasonable</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макалкии</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Makolkin</surname><given-names>V. I.</given-names></name></name-alternatives><email xlink:type="simple">dvmak@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московская медицинская академия им. И.М.Сеченова, г. Москва</institution></aff><aff xml:lang="en"><institution>I.M. Sechenov Moscow Medical Academy. Moscow</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2008</year></pub-date><volume>7</volume><issue>8</issue><fpage>80</fpage><lpage>84</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Макалкии В.И., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Макалкии В.И.</copyright-holder><copyright-holder xml:lang="en">Makolkin V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1733">https://cardiovascular.elpub.ru/jour/article/view/1733</self-uri><abstract/><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>антигипертензивная комбинированная терапия</kwd><kwd>тиазидные диуретики</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>combined antihypertensive therapy</kwd><kwd>thiazide diuretics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профил забол укреп здор 2001; 2: 3-7.</mixed-citation><mixed-citation xml:lang="en">Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профил забол укреп здор 2001; 2: 3-7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск тер профил 2004; 3(3), ч.1: 10-4.</mixed-citation><mixed-citation xml:lang="en">Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск тер профил 2004; 3(3), ч.1: 10-4.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Neuton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. JAMA 1993; 270: 713-24.</mixed-citation><mixed-citation xml:lang="en">Neuton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. JAMA 1993; 270: 713-24.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">SHEP Cooperative Reseach Group. Prevention of stroke by antihypertensive drug treatment in older person withisolated systolis hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991; 265: 3255-64.</mixed-citation><mixed-citation xml:lang="en">SHEP Cooperative Reseach Group. Prevention of stroke by antihypertensive drug treatment in older person withisolated systolis hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991; 265: 3255-64.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, LindholmLH, HanssonL, etal. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, LindholmLH, HanssonL, etal. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Medical research council worcing party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.</mixed-citation><mixed-citation xml:lang="en">Medical research council worcing party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT officers and coordinators for the ALLHAT collaborative reseach group.Major outcomes in bighrisk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calciumchannel blocker vs diuretic. JAMA 2002; 288: 2981-97.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT officers and coordinators for the ALLHAT collaborative reseach group.Major outcomes in bighrisk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calciumchannel blocker vs diuretic. JAMA 2002; 288: 2981-97.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor AL, Wright JT. Importance of Race/Ethnicy in Clinical Trials. Lesson From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). Circulation 2005; 112: 3654-66.</mixed-citation><mixed-citation xml:lang="en">Taylor AL, Wright JT. Importance of Race/Ethnicy in Clinical Trials. Lesson From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). Circulation 2005; 112: 3654-66.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sleight P, Yusuf S. New evidence on the importance of renninangiotensin system in the treatment of higher-risk patiens with hypertension. J Hypertens 2003; 21(9): 1599-608.</mixed-citation><mixed-citation xml:lang="en">Sleight P, Yusuf S. New evidence on the importance of renninangiotensin system in the treatment of higher-risk patiens with hypertension. J Hypertens 2003; 21(9): 1599-608.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Psaty BM. Health outcomes associated with various antihypertensive therapies used as a first line agents. A Network meta-analysis. JAMA 2003; 289: 2534-44.</mixed-citation><mixed-citation xml:lang="en">Psaty BM. Health outcomes associated with various antihypertensive therapies used as a first line agents. A Network meta-analysis. JAMA 2003; 289: 2534-44.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, Sever PS, PoulterNR, etal. Prevention of cardiovascular events with an antihypertensive regimes of amlodipine adding perindopril as reguired versus atenjlol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure Lowering Arm (ASCOT-BPLA): a muticentre randomised controlled trial. Lnced 2005; 366: 895-906.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, Sever PS, PoulterNR, etal. Prevention of cardiovascular events with an antihypertensive regimes of amlodipine adding perindopril as reguired versus atenjlol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure Lowering Arm (ASCOT-BPLA): a muticentre randomised controlled trial. Lnced 2005; 366: 895-906.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof D, Devereux RB, Kjeldsen, etal. Cardiovascular morbidity and mortality in the losartan intervention for Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995-1003.</mixed-citation><mixed-citation xml:lang="en">Dahlof D, Devereux RB, Kjeldsen, etal. Cardiovascular morbidity and mortality in the losartan intervention for Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995-1003.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pepine CJ, Handberg-Thurmond E, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). JACC 1998; 32: 1228-37.</mixed-citation><mixed-citation xml:lang="en">Pepine CJ, Handberg-Thurmond E, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). JACC 1998; 32: 1228-37.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mercuri M, Henning M, Zanchetti A, et al. Several articles presenting the different aspects of ELSA Blood Press 1996; 5(Suppl 4): 20-52.</mixed-citation><mixed-citation xml:lang="en">Mercuri M, Henning M, Zanchetti A, et al. Several articles presenting the different aspects of ELSA Blood Press 1996; 5(Suppl 4): 20-52.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Grasswi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J of Hypertens 2006; 24: 3-10.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Grasswi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J of Hypertens 2006; 24: 3-10.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В. Комбинированная антигипертензивная терапия: есть ли шансы у ЛОДОЗА? Фарматека 2008; 15: 9-14.</mixed-citation><mixed-citation xml:lang="en">Недогода С.В. Комбинированная антигипертензивная терапия: есть ли шансы у ЛОДОЗА? Фарматека 2008; 15: 9-14.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jounela AJ, Lilya M, Lumme J. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effect. Blood Press 1994; 3(4): 231-5.</mixed-citation><mixed-citation xml:lang="en">Jounela AJ, Lilya M, Lumme J. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effect. Blood Press 1994; 3(4): 231-5.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sarafidis P, Barkis GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes care 2006; 29: 1167-9.</mixed-citation><mixed-citation xml:lang="en">Sarafidis P, Barkis GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes care 2006; 29: 1167-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez JG, Rodriguez-Perez JC, Garrido J, et al. Effect of two antihypertensive combinations on metabolic control in type-2 dibetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.</mixed-citation><mixed-citation xml:lang="en">Fernandez JG, Rodriguez-Perez JC, Garrido J, et al. Effect of two antihypertensive combinations on metabolic control in type-2 dibetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider M. Metabolic neutralitymof combined verapamil-trandolapril tratment in contrast to beta-blocker-low dose and chlortalidone in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-77.</mixed-citation><mixed-citation xml:lang="en">Schneider M. Metabolic neutralitymof combined verapamil-trandolapril tratment in contrast to beta-blocker-low dose and chlortalidone in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-77.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">2007 Guidelines for the Management of Arterial Hypertension. J of Hypertens 2007; 25: 1105-87.</mixed-citation><mixed-citation xml:lang="en">2007 Guidelines for the Management of Arterial Hypertension. J of Hypertens 2007; 25: 1105-87.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103-13.</mixed-citation><mixed-citation xml:lang="en">Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103-13.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Buhtel FR, Berglund G, Anderson OK, et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144-6.</mixed-citation><mixed-citation xml:lang="en">Buhtel FR, Berglund G, Anderson OK, et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144-6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987; 8(Suppl.M): 65-9.</mixed-citation><mixed-citation xml:lang="en">Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987; 8(Suppl.M): 65-9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Ven LM. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 1: 16-22.</mixed-citation><mixed-citation xml:lang="en">Van der Ven LM. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 1: 16-22.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55-67.</mixed-citation><mixed-citation xml:lang="en">Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55-67.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">FrishmanWH, Brizzynski BS, Coulson LR, et al. A multifactorial trial design to assess cjmbination therapy in hypertension: treatment with Bissoprolol and Hydrochlorothiazide. Arch Intern Med 1994; 154: 1461-8.</mixed-citation><mixed-citation xml:lang="en">FrishmanWH, Brizzynski BS, Coulson LR, et al. A multifactorial trial design to assess cjmbination therapy in hypertension: treatment with Bissoprolol and Hydrochlorothiazide. Arch Intern Med 1994; 154: 1461-8.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Frishman WH, Burris Jf, Mroczek WJ, et al. First-line therapy jhtion with lowe0dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182-8.</mixed-citation><mixed-citation xml:lang="en">Frishman WH, Burris Jf, Mroczek WJ, et al. First-line therapy jhtion with lowe0dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182-8.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Neutel JM, Rolf CN, Valentine SN, et al. Low-dose combination therapy as fist line treatment of mild to moderate hypertension: the efficacy and safety of Bisoprolol/6,25 HCTZ versus Amlodipine, Enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33-45.</mixed-citation><mixed-citation xml:lang="en">Neutel JM, Rolf CN, Valentine SN, et al. Low-dose combination therapy as fist line treatment of mild to moderate hypertension: the efficacy and safety of Bisoprolol/6,25 HCTZ versus Amlodipine, Enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33-45.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative forst-line approach to hyperttension treatment. Am Heart J 1995; 130: 359-66.</mixed-citation><mixed-citation xml:lang="en">Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative forst-line approach to hyperttension treatment. Am Heart J 1995; 130: 359-66.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Papademetriou V, Neutel JM, Narayan P, et al. Comparison of Bisoprolol and low-dose Hydrochlorohtiazide combination with Losartan, alone or in combination Wth hydrochlorothiazide in the hreatment of hupertension; a double blind, randomized, placebo-controlled trial. CVR R 1998; 1-8.</mixed-citation><mixed-citation xml:lang="en">Papademetriou V, Neutel JM, Narayan P, et al. Comparison of Bisoprolol and low-dose Hydrochlorohtiazide combination with Losartan, alone or in combination Wth hydrochlorothiazide in the hreatment of hupertension; a double blind, randomized, placebo-controlled trial. CVR R 1998; 1-8.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
